Galectin-3在脑膜瘤中的表达及其与术后复发的关系  

The relationship between Galectin-3 expression in Meningioma and postoperative recurrence

作　　者：马金邦[1] 李秀敏[2] 张庆华[3] 张莉[3] 王涛[1] 李宗正[3] 魏健强[1] 夏志强[1] 

机构地区：[1]宁夏医科大学,宁夏银川750004 [2]山东省聊城市第二人民医院,山东聊城252600 [3]宁夏医科大学附属医院,宁夏银川750004

出　　处：《宁夏医学杂志》2011年第3期212-214,F0002,共4页Ningxia Medical Journal

基　　金：宁夏科技攻关项目(NK2010)

摘　　要：目的研究Galectin-3在脑膜瘤中的表达水平及其与脑膜瘤术后复发的关系。方法收集行Simpson Ⅰ级切除治疗并经至少5年随访的60例脑膜瘤患者的临床资料,采用SP免疫组化法,检测病理标本中Galectin-3蛋白表达水平;结合患者的临床资料,对脑膜瘤病理标本的Galectin-3蛋白表达进行统计学分析。结果 Galectin-3在不同级别的脑膜瘤中表达具有统计学意义(P<0.05),Galectin-3在恶性脑膜瘤及非典型性脑膜瘤中的表达明显高于良性脑膜瘤;Galectin-3的表达在良性复发组明显高于良性未复发组(P<0.05)。结论 Galectin-3蛋白的表达水平与脑膜瘤病理分型有一定关系,其表达水平随着脑膜瘤WHO病理分级的增加而增高;Galectin-3表达情况可作为判断良性脑膜瘤有无复发的辅助指标之一。Objective To study the relation between the expression of Galectin -3 and meningioma postoperative recurrence. Methods Sixty patients were collected in this study who applied Simpson level - I resection, pathologically confirmed as meningioma, and they were followed up for at least 5 years. Then Galectin - 3 protein was determined in pathological tissues by immunohistochemical method, and differences of Galectin - 3 expression were observed in different categories. Results The expression of Galectin - 3 protein in different pathological grade of meningiomas were significant differences （ P 〈 0.05 ）, the expression of Galectin - 3 protein in malignant meningiomas and atypical meningiomas was significantly higher than that in benign meningiomas （ P 〈 0.05 ）. The expression of Galectin - 3 protein in recurrent benign meningiomas group were significantly higher than that in the non recurrent benign meningiomas group （ P 〈 0.05）. Conclusion The expression of Galectin - 3 protein in meningioma pathology and tumor recurrence has a certain relationship, which is higher with the increase of meningioma WHO pathological grade. The expression of Galectin - 3 can be used as one of auxiliary indicators which can be used to determine whether the possibility of benign meningiomas＇recurrence.

关 键 词：脑膜瘤 复发 GALECTIN-3 

分 类 号：R739.45[医药卫生—肿瘤]